This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 May 15;319(19):1985-1987.

doi: 10.1001/jama.2018.4852.

Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea

Elizabeth W Loder¹, Matthew S Robbins²

Affiliations

Affiliations

¹ Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Jack D. Weiler Hospital, Montefiore Medical Center, Inpatient Services, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York.

PMID: 29800193
DOI: 10.1001/jama.2018.4852

Editorial

Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea

Elizabeth W Loder et al. JAMA. 2018.

. 2018 May 15;319(19):1985-1987.

doi: 10.1001/jama.2018.4852.

Authors

Elizabeth W Loder¹, Matthew S Robbins²

Affiliations

¹ Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Jack D. Weiler Hospital, Montefiore Medical Center, Inpatient Services, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York.

PMID: 29800193
DOI: 10.1001/jama.2018.4852

No abstract available

PubMed Disclaimer

Comment on

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Dodick DW, et al. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853. JAMA. 2018. PMID: 29800211 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations